2-pyrrolidinone moiety is not critical for the cognition-enhancing activity of piracetam-like drugs.

[1]  S. Irwin,et al.  Comprehensive observational assessment: Ia. A systematic, quantitative procedure for assessing the behavioral and physiologic state of the mouse , 1968, Psychopharmacologia.

[2]  Maria Novella Romanelli,et al.  Design and study of piracetam-like nootropics, controversial members of the problematic class of cognition-enhancing drugs. , 2002, Current pharmaceutical design.

[3]  C. Ghelardini,et al.  Molecular simplification of 1,4-diazabicyclo[4.3.0]nonan-9-ones gives piperazine derivatives that maintain high nootropic activity. , 2000, Journal of medicinal chemistry.

[4]  T. Nishizaki,et al.  Nefiracetam facilitates hippocampal neurotransmission by a mechanism independent of the piracetam and aniracetam action , 2000, Brain Research.

[5]  K. Nakamura,et al.  Serotonergic mechanisms involved in the attentional and vigilance task performance of rats and the palliative action of aniracetam , 2000, Naunyn-Schmiedeberg's Archives of Pharmacology.

[6]  C. Ghelardini,et al.  Design, synthesis, and preliminary pharmacological evaluation of 1, 4-diazabicyclo[4.3.0]nonan-9-ones as a new class of highly potent nootropic agents. , 2000, Journal of medicinal chemistry.

[7]  M. Raiteri,et al.  Activity of putative cognition enhancers in kynurenate test performed with human neocortex slices. , 1999, The Journal of pharmacology and experimental therapeutics.

[8]  G. Rose,et al.  Cognition enhancement strategies by ion channel modulation of neurotransmission. , 1999, Current pharmaceutical design.

[9]  T. Narahashi,et al.  Modulation of the neuronal nicotinic acetylcholine receptor-channel by the nootropic drug nefiracetam , 1999, Brain Research.

[10]  K. Nakamura,et al.  Apomorphine-induced hypoattention in rats and reversal of the choice performance impairment by aniracetam. , 1998, European journal of pharmacology.

[11]  Sung Ju Cho,et al.  Investigations of Novel Azomethine Ylide‐Forming Photoreactions of N‐ Silylmethylimides. , 1995 .

[12]  J. Lehmann,et al.  Effects of putative cognition enhancers on the NMDA receptor by [3H]MK801 binding. , 1995, European journal of pharmacology.

[13]  A. Senning,et al.  SYNTHETIC AND ANALYTICAL ASPECTS OF THE CHEMISTRY OF PIRACETAM-TYPE SUBSTITUTED PYRROLIDINES. A REVIEW , 1995 .

[14]  Sung Ju Cho,et al.  Investigations of Novel Azomethine Ylide-Forming Photoreactions of N-Silylmethylimides , 1995 .

[15]  B. Testa,et al.  X-ray crystal structure, partitioning behavior, and molecular modeling study of piracetam-type nootropics: insights into the pharmacophore. , 1995, Journal of medicinal chemistry.

[16]  A. Senning,et al.  Piracetam and other structurally related nootropics , 1994, Brain Research Reviews.

[17]  F. Mauguière,et al.  Long‐term and high‐dose piracetam treatment of Alzheimer's disease , 1993, Neurology.

[18]  R. Mazurkiewicz.  An Efficient Synthesis of N,N-Disubstituted 5-Aminooxazoles , 1992 .

[19]  G. Pepeu,et al.  Nootropic drugs and brain cholinergic mechanisms , 1989, Progress in Neuro-Psychopharmacology and Biological Psychiatry.

[20]  W. Fröstl,et al.  The Families of Cognition Enhancers , 1989, Pharmacopsychiatry.

[21]  C. Mondadori,et al.  The Effects of Nootropics on Memory: New Aspects for Basic Research , 1989, Pharmacopsychiatry.

[22]  W. Herrmann,et al.  Psychostimulants, analeptics, nootropics: an attempt to differentiate and assess drugs designed for the treatment of impaired brain functions. , 1988, Pharmacopsychiatry.

[23]  C. Perrin,et al.  Absence of stereoelectronic control in hydrolysis of cyclic amidines. , 1986, Journal of the American Chemical Society.

[24]  E. Pinto,et al.  [Psychostimulants]. , 1968, Revue medicale de Liege.

[25]  M. Jarvik,et al.  An Improved One-Trial Passive Avoidance Learning Situation , 1967, Psychological reports.

[26]  C. Giurgea,et al.  A GABA-related hypothesis on the mechanism of action of the antimotion sickness drugs. , 1967, Archives internationales de pharmacodynamie et de therapie.

[27]  C. Niemann,et al.  The Interaction of α-Chymotrypsin with a Series of α-N-Acetyl-α-amino Acid Methylamides1 , 1959 .

[28]  D. McLachlan.  X-ray crystal structure , 1957 .

[29]  O. Brady,et al.  CCCXX.—The isomerism of the oximes. Part XXVIII. The Beckmann rearrangement of the N-methyl ethers of aldoximes , 1926 .